🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 78 of 857 · Phase 3 first, then by program name

  1. Guselkumab, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab 1 mL PFS Placebo, Guselkumab 2 mL PFS Placebo

    Janssen-Cilag International N.V.

    Moderate to Severly Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  2. Guselkumab, Placebo 0.5ml equivalent, Guselkumab- Solution for infusion- 10 mg/ml, Placebo 2.0ml equivalent, Guselkumab, Placebo 1.0ml equivalent, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  3. Guselkumab- Solution for infusion- 10 mg/ml, Placebo to Guselkumab, Placebo to Guselkumab solution for injection in pre-filled syringe -100 mg/ml, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, Placebo to Guselkumab- Solution for infusion- 10 mg/ml

    Janssen-Cilag International N.V.

    Fistulizing perianal Crohn's Disease

    phase 3 small molecule active

    1 trial

  4. Gynaecological follow-up

    GlaxoSmithKline

    Infections, Papillomavirus

    phase 3 other completed

    1 trial

  5. H. pylori vaccine

    BRIGHT MINDS BIOSCIENCES INC.

    H. Pylori Infection

    phase 3 mab completed

    1 trial

  6. H. pylori vaccine

    Jiangsu Province Centers for Disease Control and Prevention

    H. Pylori Infection

    phase 3 mab completed

    1 trial

  7. H006629, H006629, H006629, LEVODOPA AND DECARBOXYLASE INHIBITOR , H006629

    Zambon SpA

    Motor fluctuations in advanced Parkinson’s disease

    phase 3 small molecule active

    1 trial

  8. H5N1 adjuvanted split virus vaccine (A/Vietnam/1194/2004 strain)

    GlaxoSmithKline

    Influenza

    phase 3 mab completed

    1 trial

  9. HBS-101, White, round, plain, biconvex film-coated tablet. Matching 4.45 mg tablet is 3.7 mm in diameter., White, round, plain, biconvex film-coated tablet. matching 17.8 mg tablet is 7.5 mm in diameter., WAKIX, HBS-101, WAKIX

    Harmony Biosciences Holdings

    Prader-Willi syndrome

    phase 3 small molecule active

    1 trial

  10. HBS-301 tablet

    Harmony Biosciences Holdings

    Idiopathic Hypersomnia

    phase 3 small molecule active

    1 trial

  11. HD201

    Prestige Biopharma Belgium

    HER2 Positive Breast Cancer

    phase 3 small molecule completed

    1 trial

  12. HEC585

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Idiopathic Pulmonary Fibrosis (IPF)

    phase 3 small molecule active

    1 trial

  13. HEC74647PA+HEC110114

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Chronic HCV Infection

    phase 3 small molecule completed

    1 trial

  14. HEPARIN , NADROPARIN

    Disc Medicine

    All patients who receive ECMO treatment during the study period in one the participating centers from which (deferred) informed consent is obtained. Patients in whom the ECMO is only used to bridge a procedure like a high risk percutaneous coronary intervention or during surgery are excluded.

    phase 3 small molecule active

    1 trial

  15. HETLIOZ 20 mg hard capsules, Placebo will be provided in size and appearance identical to those containing tasimelteon and will be administered orally.

    Lacuna Pharma Pty Ltd

    Delayed Sleep-Wake Phase Disorder (DSWPD)

    phase 3 small molecule active

    1 trial

  16. HIPEC with neoadjuvant chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Cancer

    phase 3 other active

    1 trial

  17. HLD200 methylphenidate hydrochloride capsules

    COLLEGIUM PHARMACEUTICAL, INC

    Attention Deficit Hyperactivity Disorder

    phase 3 small molecule terminated

    1 trial

  18. HLX02

    Shanghai Henlius Biotech

    Breast Cancer

    phase 3 mab completed

    1 trial

  19. HOLOXAN 2000 mg, poudre pour usage parentéral, DETICENE 100 mg, poudre et solvant pour solution pour perfusion, DOXORUBICINE ACCORD 2 mg/ml, solution pour perfusion

    The George Institute

    Resectable, non-metastatic soft-tissue sarcoma (STS)

    phase 3 small molecule active

    1 trial

  20. HS-20094 Injection

    Jian Li

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  21. HUMAN NORMAL IMMUNOGLOBULIN (IV), Placebo for empasiprubart- solution for IV infusion, Placebo for IVIg - solution for IV infusion, ARGX-117

    argenx

    Chronic inflammatory demyelinating polyneuropathy (CIDP)

    phase 3 small molecule active

    1 trial

  22. HVA

    The First People's Hospital of Lianyungang

    Newly Diagnosed Acute Myeloid Leukemia With High Risk

    phase 3 small molecule active

    1 trial

  23. HYCAMTIN 4 mg powder for concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion

    Gilead Sciences Pty Limited

    Extensive Stage Small Cell Lung Cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  24. HYDROCORTISONE, PREDNISONE ACETATE, ENZALUTAMIDE, DEXAMETHASONE ACETATE, PREDNISONE, Opevesostat, ABIRATERONE ACETATE, DEXAMETHASONE, HYDROCORTISONE , HYDROCORTISONE, FLUDROCORTISONE, ABIRATERONE ACETATE, PREDNISOLONE, HYDROCORTISONE, FLUDROCORTISONE ACETATE

    Merck Sharp and Dohme

    Metastatic castration resistant prostate cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources